Bibliografías temáticas / Liquid biopsy

Índice

Artículos de revistas
Tesis
Libros
Capítulos de libros
Actas de conferencias
Informes

Literatura académica sobre el tema "Liquid biopsy"

Autor: Grafiati

Publicado: 4 de junio de 2021

Última modificación: 7 de julio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Liquid biopsy".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Artículos de revistas sobre el tema "Liquid biopsy"

Singh, Pratibha, Meenakshi Gothwal y Garima Yadav. "Liquid Biopsy in Ovarian Cancer". Indian Journal of Obstetrics and Gynecology 6, n.º 4 (2018): 427–31. http://dx.doi.org/10.21088/ijog.2321.1636.6418.16.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Jain, Amit Kumar, Guruprasad Bhat, Vineet Govinda Gupta y Hari Goyal. "Liquid Biopsy". Indian Journal of Medical and Paediatric Oncology 42, n.º 01 (marzo de 2021): 077–79. http://dx.doi.org/10.1055/s-0041-1729434.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Goodwin, Peter M. "Liquid Biopsy". Oncology Times 38, n.º 13 (julio de 2016): 40. http://dx.doi.org/10.1097/01.cot.0000489521.34002.61.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Siddiqua, Umme Iffat. "Liquid Biopsy". KYAMC Journal 10, n.º 1 (22 de mayo de 2019): 1. http://dx.doi.org/10.3329/kyamcj.v10i1.41473.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Gingras, Isabelle, Roberto Salgado y Michail Ignatiadis. "Liquid biopsy". Current Opinion in Oncology 27, n.º 6 (noviembre de 2015): 560–67. http://dx.doi.org/10.1097/cco.0000000000000223.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Lavine, M. S. "Liquid Biopsy". Science 328, n.º 5975 (8 de abril de 2010): 141. http://dx.doi.org/10.1126/science.328.5975.141-a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hekmat, K. y C. Bruns. "„Liquid biopsy“". Der Chirurg 90, S2 (13 de febrero de 2019): 120. http://dx.doi.org/10.1007/s00104-019-0845-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Hekmat, K. y C. Bruns. "„Liquid biopsy“". Der Chirurg 88, n.º 7 (14 de junio de 2017): 621. http://dx.doi.org/10.1007/s00104-017-0458-4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Fulmer, Tim. "Liquid biopsy". Science-Business eXchange 5, n.º 26 (junio de 2012): 668. http://dx.doi.org/10.1038/scibx.2012.668.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Imyanitov, E. N., E. Sh Kuligina y G. A. Janus. "LIQUID BIOPSY IN CLINICAL ONCOLOGY". Practical oncology 23, n.º 4 (30 de diciembre de 2022): 211–24. http://dx.doi.org/10.31917/2304211.

Texto completo

Resumen

Liquid biopsy is the analysis of tumor fragments (entire cells, nucleic acids,proteins) in hysiological and pathological body liquids. This technology has already been included in standard procedures of detecting secondary mutations, which are associate with acquired drug resistance. Liquid biopsy is a promising tool for early cancer detection, evaluation of the success of radical cancer surgery, monitoring of residual tumor disease, assessment of treatment efficacy etc.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Tesis sobre el tema "Liquid biopsy"

Abbou, Samuel. "Liquid Biopsy in Pediatric Sarcoma". Thesis, université Paris-Saclay, 2022. http://www.theses.fr/2022UPASL037.

Texto completo

Resumen

Résumé : Les biopsies liquides ouvrent de nouveaux champs d'applications dans la prise en charge des patients au diagnostic, au cours de leur suivi et également en recherche translationnelle. Ces dernières années, de nombreux efforts ont été consacrés au développement de l'ADN tumoral circulant (ADNct) et des cellules tumorales circulantes (CTC). Il y a malgré tout de nombreux terrains encore en friches dans les cancers de l'enfant, et parmi eux dans les sarcomes pédiatriques.Nous avons souhaité explorer dans ce travail différents aspects des applications cliniques éventuelles et d'utilisation de ces technologies pour la compréhension de la biologie des tumeurs. La première partie de ce projet est une revue de la littérature qui se rapporte à l'application de l'ADNct dans les cancers solides pédiatriques. Nous présentons ensuite un travail de recherche qui vise à utiliser les CTC à visée diagnostique dans les sarcomes à translocation. Cette étude présente une approche permettant d'identifier des fusions pathognomoniques de sarcome à partir de très faibles quantités de tissu fixé, de CTC sur des modèles murins ou chez des patients. La deuxième étude présentée s'intéresse à la détection de l'ADNct au diagnostic de rhabdomyosarcome en utilisant les altérations de nombre de copie de chromosome, les réarrangements chromosomiques et les variants de nucléotide. Nous avons démontré que la détection au diagnostic est faisable et a un impact pronostique fort sur le devenir des patients. La dernière partie de ce manuscrit présente le développement d'un processus de traitement d'échantillons de patient pour détecter et isoler des cellules tumorales circulantes dans le but d'analyser les particularités génomiques de cette population à une résolution cellulaire.Ce travail explore certains aspects de l'utilisation de la biopsie liquide dans les sarcomes pédiatriques, parmi de nombreux autres. Il est crucial dans le développement de ce champ de recherche, de maîtriser les particularités intrinsèques de chaque type tumoral et des technologies disponibles. Nous avons démontré l'utilité d'une telle approche au diagnostic dans deux applications. Cette aire de recherche ouvre de nombreuses possibilités qui appellent à poursuivre les efforts afin d'élargir les applications en recherche et en clinique
Abstract: Liquid biopsy is an opportunity for improved diagnosis, treatment monitoring and genomic studies in oncology. Substantial effort in recent years has focused on circulating tumor DNA (ctDNA) and circulating tumor cells (CTC). However, pediatric cancer, including sarcomas, are still largely unexplored disease areas in this field.In this work, we sought to explore several aspects of liquid biopsy applied to pediatric sarcomas including their clinical use at diagnosis and as a tool to understand tumor biology. We first present a review of the literature demonstrating the feasibility of applying liquid biopsy to pediatric solid malignancies. Then, we report a methodological study using CTC for diagnostic purposes in translocation driven sarcomas. This approach identified fusions from as little as two unstained slides of FFPE tumor biopsy tissue, from CTC collected from tumor-bearing mice, and from liquid biopsy samples from patients with known fusion-positive cancers. The second study focuses on ctDNA for prognostication at the time of diagnosis in rhabdomyosarcoma by detecting copy number alterations, rearrangements, and single-nucleotide variants. Our study demonstrates that baseline ctDNA detection is feasible and has prognostic value. The last part of this work presents the development of a workflow to isolate single sarcoma cancer cells for sequencing, with an ultimate goal to analyze CTC genomic features at a single-cell resolution.This work explores several clinically and scientifically relevant aspects of liquid biopsy in pediatric sarcoma. We showed that liquid biopsy has utility at diagnosis in two different applications. Further development in this field will require a strong knowledge of tumor-specific biology, the clinical care of patients with these diseases, and the adaption of new technologies. My findings demonstrate the transformative possibilities this research may bring to the care of patients with pediatric sarcomas

Los estilos APA, Harvard, Vancouver, ISO, etc.

BARBARESCO, FEDERICA. "Microfluidic devices: application for liquid biopsy". Doctoral thesis, Politecnico di Torino, 2021. http://hdl.handle.net/11583/2903504.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

GIORDANI, Elena. "Liquid Biopsy in Real Life Oncology". Doctoral thesis, Università degli studi di Ferrara, 2022. http://hdl.handle.net/11392/2481324.

Texto completo

Resumen

Secondo il report “I numeri del cancro in Italia 2020” dell’Associazione italiana registri tumori (AIRTUM) e l’Associazione italiana di oncologia medica (AIOM), il tumore al seno resta la neoplasia più frequente in Italia e la prima causa di morte per tumore nelle donne. Il sottotipo HER2+ rappresenta il 30% dei tumori al seno ed è associato ad una prognosi infausta, sebbene l’utilizzo di terapie mirate abbia reso questo sottotipo curabile come altri biologicamente meno aggressivi. Tuttavia, i pazienti in stadio avanzato, trattati con terapie antiHER2, spesso sviluppano resistenza al trattamento. La biopsia liquida (BL) è una metodica minimamente invasiva, di facile utilizzo, sensibile e specifica, in grado di individuare l’insorgenza della resistenza anche prima che questa si manifesti clinicamente, permettendo così di ridurre tossicità e costi di un trattamento inefficace. I pazienti che presentano alterazioni di HER2 beneficiano di una terapia mirata con molti inibitori. Il monitoraggio longitudinale tramite BL dovrebbe diventare un fattore chiave nella gestione della malattia e nella scelta della strategia terapeutica più appropriata, poiché tiene conto dell'idea di evoluzione del cancro nel contesto dei principi generali dell'oncologia di precisione. Ad oggi, lo stato di HER2 viene assegnato mediante una combinazione di Immunoistochimica e Ibridazione in Situ (IHC/ISH) su tessuto, in una scala binaria che separatamente valuta la sovra espressione e l'amplificazione genica. Ipotizzo che questo schema diagnostico (CDx), statico, una tantum, solo su tessuto, debba essere rivisto o abbandonato poiché assegna dei cut-off definiti per la terapia convenzionale antiHER2 (ad esempio, un tumore è HER2+ oppure no). Questa visione è probabilmente semplicistica, perché i nuovi agenti antiHER2 possono colpire sia i tumori HER2-alti che HER2-bassi, considerando che i livelli di HER2 diminuiscono durante la terapia. In questa tesi, propongo che i livelli di HER2 vengano valutati longitudinalmente, (su una scala continua, e in maniera bimodale), correlando la sovra espressione e la variazione del numero di copie (CNV) di HER2 e co-fattorizzandoli in un nuovo CDx. Questo permetterebbe la riallocazione dinamica dei pazienti ai diversi sottotipi e l’assegnazione di un trattamento non standard in un contesto dinamico che modifichi la pratica clinica comune. Presento dei dati che dimostrano come la BL possa aiutare nel ridisegnare il CDx nel cancro al seno avanzato. Riassumo LiqBreasTrack, un recente studio di NGS, condotto durante la mia tesi (Allegretti, Fabi; Molecular Cancer 2021) e descrivo HER2-2D, un saggio bidimensionale inedito di BL che stima le CNV e il livello di proteina di HER2 nella prima e nella seconda dimensione, rispettivamente. Il test sfrutta saggi custom di dPCR e un ELISA commerciale, è ugualmente applicabile a tessuti e sangue e dà come output finale un punteggio di HER2 cumulativo. L'applicazione principale è nel sangue, e descriverò un sottogruppo di tumori/pazienti con cancro al seno in stadio avanzato elettivamente suscettibili al blocco di HER2 da parte di Trastuzumab Emtansine (T-DM1), un potente anticorpo-coniugato a farmaco (ADC). Accennerò ad una collaborazione con il gruppo del Prof. F. Michelotti (Università Sapienza di Roma), orientata allo sviluppo di un biosensore Surface Plasmon Resonance Imaging (SPRI) per la rilevazione rapida, semplice e senza marcatura estrinseca degli anticorpi antiHER2, per future applicazioni in ambito dell’Health Technology Assessment. In sintesi, attraverso la BL dimostro che HER2 è una caratteristica adattiva dei tumori, e i suoi cambiamenti (tra quelli genomici più generali) nel sangue possono essere studiati per assegnare in modo adattivo terapie bersaglio a coorti definite di pazienti con cancro al seno caratterizzate da diversi gradi di dipendenza oncogenica da HER2.
According to the data contained in the report "I numeri del cancro in Italia 2020" edited by the Italian Association of Tumour Registers (AIRTUM) and the Italian Association of Medical Oncology (AIOM), breast cancer remains the most frequent neoplasm in Italy and the leading cause of death from cancer in women. HER2+ subtype breast cancers represent 30% of all breast cancers and used to be associated with a poor prognosis, although the application of targeted HER2 blockade has rendered this subtype at least as curable as other biologically less aggressive breast cancer subtypes. Unfortunately, patients with advanced breast cancer treated with anti-HER2 therapies almost invariably develop pharmacological resistance. Liquid biopsy (LB) is minimally invasive, easy to perform, highly sensitive and specific. It may detect molecular traits of resistance even before clinical manifestations of progression, which may reduce unnecessary anti-HER2 treatment, abating unwanted side effects, toxicity, and treatment-associated costs. Patients with tumors bearing HER2 alterations benefit from target therapy with many specific inhibitors. Longitudinal monitoring by LB is expected to become a key factor in disease management and the use of these targeted therapies, because it takes into account the idea of cancer evolution in the context of the general principles of precision oncology. The HER2 status is presently assessed by a combination of Immunohistochemistry and In Situ Hybridization (IHC/ISH) to detect gene overexpression and amplification in tissues on a binary scale that separately factors overexpression and gene amplification. I hypothesize that a static, one-time-only, tissue-only HER2 Companion Diagnostics (CDx), like the one we presently use, should be revised, or dismissed. This scale assigns defined cut-offs for conventional HER2 blockade therapy, e.g., tumors are either HER2 or non-HER2. This view is probably simplistic, because novel anti HER2 agents may effectively target both HER2-high and HER2-low tumors, and HER2 levels wane during therapy. In this thesis, I defend the hypothesis that HER2 functional expression should be assessed longitudinally (on a continuous scale, and bimodally), e.g. (over)expression and Copy Number Variation (CNV) should be fully co-factored into a novel CDx scheme, enabling dynamic reallocation of patients to different subtypes and assign non-standard treatment in a potentially practice-changing setting. I present data showing that LB may help redesigning CDx in advanced breast cancer. As an example, I briefly summarize LiqBreasTrack, a recent LB NGS study, carried out during my thesis, published at the time of writing (Allegretti M., Fabi A. et al. Molecular Cancer 2021). I also describe HER2-2D, a bidimensional LB assay that estimates HER2 CNV and HER2 protein level in the first and second dimensions, respectively. This is presently unpublished and personally developed. The assay takes advantage of customized digital PCR and a commercial ELISA, it is equally applicable to tissues and blood, and yields a cumulative HER2 score. HER2-2D main application is in blood, and I will describe a subset of breast cancer tumors/patients electively susceptible to HER2 blockade by Trastuzumab Emtansine (T-DM1), a potent Antibody-Drug Conjugate (ADC) targeting HER2. I will briefly mention a collaboration with the laboratory of Prof. Francesco Michelotti at the University of Sapienza, Rome, aimed at the construction of a novel Surface Plasmon Resonance Imaging (SPRI) biosensor for the rapid, simple and label-free detection of HER2, for future applications in the Health Technology Assessment area. In summary, thorough LB we show that HER2 is an adaptive tumor feature, and that its changes (amongst more general genomic changes) in blood may find application to adaptively assign target therapy to defined, distinct cohorts of breast cancer patients characterized by different degrees of HER2 oncogenic addiction.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Palmieri, Maria. "CfDNA-NGS Liquid Biopsy for solid cancers and vascular malformations". Doctoral thesis, Università di Siena, 2020. http://hdl.handle.net/11365/1120548.

Texto completo

Resumen

The liquid biopsy is a new emerging and repeatable low risky approach able to detect drive mutations that characterize the tumor, to monitor cancer evolution over time, and to overcome the standard tissue biopsy limits. The biomarker par excellence is the circulating cell-free DNA (cfDNA) that was the principal leading actor of this study. The scope of this study was to perform different liquid biopsy analysis both in metastatic cancer and in vascular malformations patients to detect, from a precision medicine perspective, the sniper clone responsible for the tumor evolution or the vascular malformations. The cfDNA was extracted from plasma coming from peripheral and/or efferent vein of vascular malformation. The obtained cfDNA was used to perform the libraries using two different genes panel of 52 and 77 cancer-driver genes, respectively the Oncomine™ Pan-Cancer Cell-Free Assay and AVENIO ctDNA Expanded Kit. The most frequent mutations that we found in metastatic patients were the SNV in TP53, follow by PIK3CA, KRAS, and CNV in FGFR3. In the majority of cases, the mutations found at first liquid biopsy were confirmed by an increased allele frequency at the second one. In vascular anomalies affected patients, the PIK3CA, MET, and KRAS mutated genes were found in Klippel-Trenaunay syndrome, in lymphovenous malformations, and in artero-venous malformations respectively, with a very low allele frequency percentage. In conclusion, repeated analysis of liquid biopsy lead to the identification of key cancer genes and the following of clonal evolution over time. Moreover, the liquid biopsy is suitable not only for cancer patients but also for the diagnosis of vascular malformation. Our data prove that in the new era of precision medicine, this novel approach, based on the combination of NGS and liquid biopsy from the efferent vein at the vascular malformation site, allows to detect even low-grade somatic mosaicism responsible for the vascular phenotype. This approach let to bypassing the need for a highly risky tissue biopsy and lead to a tailored personalized treatment.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Soda, Narshone. "Advanced Liquid Biopsy Technologies for Circulating Cancer Biomarker Detection". Thesis, Griffith University, 2021. http://hdl.handle.net/10072/406071.

Texto completo

Resumen

Epithelial ovarian cancer is one of the most prevalent gynaecological cancers in women and is often diagnosed in the late stage due to the mild symptoms. Currently, ovarian cancer screening is reliant on the prevailing usage of blood based CA125 protein biomarker and transvaginal ultrasound which can detect ovarian cancer in the preclinical phase in a substantial portion of cases. However, there are also other elements that can result in elevated CA125 levels such as menstruation, endometriosis or ovarian cysts. As such, the lack of accurate disease risk classification during ovarian cancer screening has led to several health burdens associated with unnecessary biopsies and overtreatment of patients. Thus, new diagnostic methods with improved sensitivity and specificity for ovarian cancer are a clinical priority. To address the enigma associated with ovarian cancer screening, liquid biopsy technologies have been developed. Molecular profiling of liquid biopsies has the potential to detect changes associated with the tumuor in collected, non-invasively body fluid samples. Detection of tumour origin biomolecules such as; circulating tumour cells (CTCs), circulating tumour specific nucleic acids (ctDNA, ctRNA, miRNAs, lnRNAs), exosomes, autoantibodies in blood, saliva, stool, urine etc. has brought about a paradigm shift in the management and diagnosis of cancer. From reliance on painful and hazardous tissue biopsies or sophisticated equipment dependent imaging, cancer management schemes are witnessing rapid evolution towards minimally invasive yet highly sensitive liquid biopsy-based tools. Clinical application of liquid biopsy is already paving the way for precision theranostics and personalised medicine, especially by enabling repeated sampling, which in turn provides a more comprehensive molecular profile of tumours. On the other hand, integration with novel miniaturised platforms, engineered nanomaterials, as well as electrochemical detection has helped in the development of low cost and simple platforms suited for point-of-care application. Despite excellent analytical performances of the existing detection methodologies, electrochemical approaches offer a promising alternative for simple, sensitive, specific, rapid, and cost effective analysis of genetic and epigenetic biomarkers in cancer samples. Therefore, innovative technology using electrochemical approach would be an effective method for the detection of biomarkers in patients with cancer. This thesis focuses on the use of nucleic acids (i.e., genetic and epigenetic) biomarkers, specifically HOX antisense intergenic RNA (HOTAIR) lncRNA and DNA methylation to identify tumour specific changes and their performance as diagnostic biomarkers in non-invasively collected biofluid samples. Novel electrochemical and colourimetric approaches have been demonstrated for the construction of a sensitive, and specific biosensor platform for the complex task of detecting and quantifying circulating ovarian cancer biomarkers. To achieve this goal, first a comprehensive literature review on the biogenesis, significance, and potential role of four widely known biomarkers (CTCs, ctDNA, miRNA and exosomes) in cancer diagnostics and therapeutics has been provided. A detailed discussion of the inherent biological and technical challenges associated with currently available methods and the possible pathways to overcome these challenges is also provided. The recent advances in the application of a wide range of nanomaterials in detecting these biomarkers are also highlighted. Next, an amplification-free electrochemical method for the detection of HOTAIR lncRNA was developed. In this method, HOTAIR sequences were magnetically isolated, purified and detected by a sandwich hybridisation method at a screen-printed gold electrode (SPE-Au). This event was monitored by amperometry using the hydrogen peroxide/horseradish peroxidase/hydroquinone (H2O2/HRP/HQ) system which enabled a catalytic enhancement of the signal. In the following chapter, a more sensitive assay was discussed which utilised colourimetric and electrochemical readout for HOTAIR detection. In this approach, subsequent detection of magnetically purified and isolated sequences was performed using the sandwich hybridisation event coupled with HRP-catalysed reaction of 3,3′,5,5′-tetramethylbenzidine (TMB) in the presence of H2O2 which facilitated the naked eye observation and enabled an alternative amperometric quantification of HOTAIR. We then explored the bioengineering and characterisation of self-assembled superparamagnetic polyhydroxybutyrate (PHB) nanobeads for the development of a platform method for the analysis of circulating biomarkers, where these nanobeads were modified with specific bio-recognition antibodies, dispersed in analyte fluids where they worked as “dispersible capture agents” to bind specific targets. The enormous active sites of PHB nanobeads allow the direct attachment of a larger number of antibodies which can significantly enhance the capture efficiency. Their magnetic property allows magnetic nanoparticle-based mixing, separation and purification which can improve assay performance by reducing the matrix effects of the biological samples, as non-target species can be removed via magnetic isolation and purification steps. Two common circulating biomarkers namely global DNA methylation and exosomes were chosen for this method. After purification and magnetic collection, the isolated targets were directly adsorbed onto a screen-printed gold electrode (SPE-Au) and electrochemically quantified using a catalytic redox cycling system of hydrogen peroxide/horseradish peroxidase/hydroquinone (H2O2/HRP/HQ). In another approach, to simplify the assay protocol, the PHB nanobeads were directly adsorbed onto the SPE-Au electrode via PHB-gold affinity interaction followed by the immune attachment of the methylated DNA targets onto the surface-bound PHB nanobeads/anti 5mC-HRP conjugates. The targets were then quantified using the similar catalytic redox cycling of H2O2/HRP/HQ. Lastly, the clinical utility of these novel technologies was demonstrated using ovarian cancer cell lines and a cohort of well-annotated patient samples. This illustrates an attempt to translate the developed technologies from an academic research phase to patient usage by assessing the clinical performance metrics. To date, there are various ovarian cancer treatment options such as surgery, chemotherapy, targeted therapy, radiation therapy and palliative treatment. Each treatment method is dependent on various factors such as the cancer stage, gene type, overall health and fitness, as well as the desire to bear children. Thus, it is envisioned that the research that integrates new cutting-edge biomarkers and innovative detection strategies (as showcased in this thesis) could advance ovarian cancer diagnosis and risk stratification in clinical settings. This will enable a more personalised treatment approach accustomed to the needs of individual patients.
Thesis (PhD Doctorate)
Doctor of Philosophy (PhD)
School of Environment and Sc
Science, Environment, Engineering and Technology
Full Text

Los estilos APA, Harvard, Vancouver, ISO, etc.

Yap, Soo Ann [Verfasser]. "Extracellular vesicles as cancer liquid biopsy biomarker / Soo Ann Yap". Berlin : Medizinische Fakultät Charité - Universitätsmedizin Berlin, 2021. http://d-nb.info/1234982889/34.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Diop, Fary. "Diffuse large B-cell lymphoma genotyping on the liquid biopsy". Doctoral thesis, Università del Piemonte Orientale, 2018. http://hdl.handle.net/11579/105207.

Texto completo

Resumen

Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is increasingly impelling in diffuse large B-cell lymphoma (DLBCL). Cell-free DNA (cfDNA) is shed into the blood by tumor cells undergoing apoptosis and can be used as source of tumor DNA for the identification of DLBCL mutations, clonal evolution, and genetic mechanisms of resistance. In this study, we aimed at tracking the basal DLBCL genetic profile and its modification upon treatment using plasma cfDNA. Ultra-deep targeted next generation sequencing of pretreatment plasma cfDNA from DLBCL patients discovered DLBCL-associated mutations that were represented in >20% of the alleles of the tumor biopsy with >90% sensitivity and~100% specificity. Plasma cfDNA genotyping also allowed for the recovery of mutations that were undetectable in the tissue biopsy, conceivably because, they were restricted to clones that were anatomically distant from the biopsy site. Longitudinal analysis of plasma samples collected under (R-CHOP) chemotherapy showed a rapid clearance of DLBCL mutations from cfDNA among responding patients. Conversely, among patients who were resistant to R-CHOP, basal DLBCL mutations did not disappear from cfDNA and, moreover, among treatment-resistant patients, new mutations were acquired in cDNA that marked resistant clones selected during the clonal evolution. These results demonstrate that cfDNA genotyping of DLBCL is as accurate as genotyping of the diagnostic biopsy to detect clonally represented somatic tumor mutations and is a real-time and noninvasive approach to tracking clonal evolution and the emergence of treatment-resistant clones

Los estilos APA, Harvard, Vancouver, ISO, etc.

Bracht-Loman, Jillian Wilhelmina Paulina. "Validation of liquid biopsy-based analysis on the NanoString nCounter platform". Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/672549.

Texto completo

Resumen

L'avaluació dels marcadors moleculars en teixit tumoral per predir el pronòstic del càncer i la resposta al tractament, també coneguda com a tractament personalitzat, ha transformat la pràctica clínica per a molts tipus de càncer. Es va descobrir que aquesta teràpia dirigida per genotipar, millora la supervivència del pacient i per tant s'han introduït diverses plataformes tècniques en els laboratoris clínics. No obstant això, no tots els tumors es poden biopsiar i, sovint, les quantitats de teixit són insuficients per a la caracterització del tumor. L'ARN, l'ADN i les proteïnes lliures circulants de biòpsies líquides, es poden extreure dels fluids corporals i poden reemplaçar o complementar les biòpsies de teixit. Les biòpsies líquides tenen diversos avantatges: la possibilitat de realització d’ estudis de serie o mínimament invasiva i permet analitzar l'heterogeneïtat tumoral. Malauradament, encara hi ha una gran bretxa entre la recerca bàsica i la implementació clínica de biòpsies líquides, principalment a causa de la manca de metodologies estandarditzades. A més, les plataformes tècniques que s'utilitzen actualment, no sempre són adequades per analitzar la baixa quantitat i qualitat de material del tumor derivat d'una biòpsia líquida. En conseqüència, la validació i implementació dels assajos de biomarcadors en biòpsies líquides en els laboratoris clínics, requereixen una plataforma tècnica estandarditzada que sigui sensible, ràpida, fàcil d'utilitzar, relativamente econòmica, flexible i amb poca quantitat de mostra. La plataforma nCounter es pot utilitzar per analitzar tota classe de molècules, inclosos ARN, ADN i proteïnes. La hibridació de codis de barres codificats per colors pels objectius d'interès permet una lectura directa dels nivells d'expressió de gens i proteïnes o la detecció de mutacions. El desenvolupament d'assaigs de biomarcadors en teixits, usant el nCounter, va conduir a l'aprovació per la FDA de l'assaig Prosigna™ per a ús clínic en la tipificació del càncer de mama. Els esforços anteriors també han destacat el potencial d'aquesta plataforma per analitzar molècules derivades i amplificades de biòpsies líquides, encara que es necessiten estudis de validació en l'entorn clínic. En aquesta tesi validem l'ús de la plataforma NanoString nCounter per analitzar material de biòpsies líquides i desenvolupar assajos de biomarcadors clínicament rellevants.
La evaluación de los marcadores moleculares en tejido tumoral para el pronóstico del cáncer y la predicción de respuesta al tratamiento (lo que habitualmente se conoce como tratamiento personalizado) ha transformado la práctica clínica a la hora de tratar muchos tipos de cáncer. Son numerosos los trabajos que desde hace tiempo respaldan el efecto que esta terapia dirigida por genotipo tiene sobre los pacientes oncológicos mejorando la supervivencia del paciente; consecuentemente, un amplio rango de plataformas técnicas han sido implementadas en los laboratorios clínicos en los últimos años. Sin embargo, no todos los tumores se pueden biopsiar y, a menudo, las cantidades de tejido son insuficientes para la caracterización del tumor. Las biopsias líquidas, como el ARN, el ADN o las proteínas circulantes tanto libres como encapsuladas en una membrana, pueden extraerse de los fluidos corporales reemplazando o complementando de este modo las tradicionales biopsias de tejido. Las biopsias líquidas tienen varias ventajas: ofrecen la posibilidad de realizar estudios seriados, son mínimamente invasivas y permiten analizar la heterogeneidad tumoral. Desafortunadamente, todavía existe una gran brecha entre la investigación básica y la implementación clínica de las biopsias líquidas, principalmente debido a la falta de metodologías estandarizadas. Además, las plataformas técnicas que se utilizan actualmente no siempre son adecuadas para analizar la baja cantidad y calidad de material del tumor procedente de una biopsia líquida. En consecuencia, la validación e implementación de los ensayos de biomarcadores en biopsias líquidas en los laboratorios clínicos requieren una plataforma técnica estandarizada que sea sensible, rápida, fácil de usar, viable económicamente, flexible y que requiera un aporte inicial de ácidos nucleicos bajo, debido a la baja concentración que normalmente se obtiene en las biopsias líquidas. La plataforma nCounter se puede utilizar para analizar todo tipo de moléculas, incluyendo ARN, ADN y proteínas. La hibridación de diferentes códigos formados por moléculas de colores siguiendo patrones específicos con secuencias de interés permite una lectura directa de los niveles de expresión de genes y proteínas o la detección de mutaciones. El desarrollo de ensayos de biomarcadores en tejidos usando nCounter condujo a la aprobación por la administración de fármacos y alimentos de los Estados Unidos (FDA) del ensayo Prosigna ™ para su uso clínico en la tipificación del cáncer de mama. Numerosos estudios han destacado el potencial de esta plataforma para analizar moléculas derivadas y amplificadas de biopsias líquidas, aunque estudios de validación en el entorno clínico aun son necesarios. El objeto de esta tesis es la validación del uso de la plataforma NanoString nCounter para analizar material de biopsias líquidas y desarrollar ensayos de biomarcadores clínicamente relevantes.
The assessment of predictive- and prognostic molecular markers in tumor tissue, also known as personalised treatment, has transformed clinical practice for many cancer types. This genotype-directed therapy was found to improve patient survival, and several technical platforms have been introduced in clinical laboratories since then. However, not all tumors can be biopsied and tissue quantities are often insufficient for tumor characterisation. Liquid biopsies, such as membrane-encapsulated- or circulating free RNA, DNA and proteins, can be derived from body fluids and can replace or complement tissue biopsies. They have several advantages, such as repeated sampling, a minimally invasive character and heterogeneous profiling. Unfortunately, there is still a big gap between basic research and clinical implementation of liquid biopsies, mainly due to the lack of standardised methodologies. In addition, currently used technical platforms are not always suitable to analyze the low quantity and quality of tumor-derived material that can be found in a liquid biopsy. In consequence, large-scale validation and clinical implementation of liquid biopsy-based biomarker assays requires a sensitive, quick, easy-to-use, relatively cheap, flexible and standardized technical platform with low input requirements. The nCounter platform can be used to analyze all types of molecules, including RNA, DNA and proteins. Binding of color coded barcodes to targets of interest allows for either a direct read-out of gene- or protein expression levels or the detection of mutations. Tissue-based biomarker assay development on nCounter led to the FDA approval of the Prosigna™ assay for clinical use in breast cancer subtyping. Previous efforts have also highlighted the potential of this platform to analyze amplified liquid biopsy-derived molecules, although validation studies in the clinical setting are needed. In this thesis we validated the use of the NanoString nCounter platform to analyze material from liquid biopsies and develop clinically relevant biomarker assays.
Universitat Autònoma de Barcelona. Programa de Doctorat en Bioquímica, Biologia Molecular i Biomedicina

Los estilos APA, Harvard, Vancouver, ISO, etc.

MARALANI, Mahafarin. "Liquid Biopsy: A Next Generation Diagnostic And Prognostic Tool In Solid Malignancies". Doctoral thesis, Università degli Studi di Palermo, 2020. http://hdl.handle.net/10447/401539.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

DO, REGO BARROS FERNANDES LIMA MARIA AUGUSTA. "Investigating Label-Free markers at Nanoscale for Liquid Biopsy Using Multimodal Microscopy". Doctoral thesis, Università degli Studi di Trieste, 2021. http://hdl.handle.net/11368/2995896.

Texto completo

Resumen

Liquid biopsy emerges as a noninvasive, easily repeatable, and potentially low-cost approach alternative to standard tissue biopsy. In most cases, it can be used to investigate the cause of symptoms or to help diagnose a number of different health conditions. Although originally used to designate analysis of non-solid tissues to screen for cancer cells, liquid biopsy also refers to the investigation of other general body fluids including its constituents characterization and not necessarily related to cancer. In this thesis, three new applications for the usage of label-free markers in the analysis of body fluid cellular constituents will be presented. Digital holographic microscopy and optical tweezers are applied to the characterization of ex-vivo generated and native red blood cells. In a second application, neutrophils precursors are characterized and classified according to its cellular and nuclear morphology during granulocytic differ- entiation. In a third proposed application, morphological markers retrieved by digital holographic microscopy are used to perform fast screening urinalysis, including leukocyturia and bacteriuria. Lastly, although not label-free, fluorescence superresolution microscopy is used to bring insights into why nuclear morphology can be used as a trustful label-free marker and shows the structural arrangement of lamin in the nucleus of neutrophil precursors with unprecedented resolution. Fast screening label-free liquid biopsies integrates the group of emerging approaches that will revolutionize the future of early disease diagnosis and therapeutic choice with disruptive impact on the society. All the investigations described in this Thesis were aimed to contribute to this promising and intriguing new scenario.
Liquid biopsy emerges as a noninvasive, easily repeatable, and potentially low-cost approach alternative to standard tissue biopsy. In most cases, it can be used to investigate the cause of symptoms or to help diagnose a number of different health conditions. Although originally used to designate analysis of non-solid tissues to screen for cancer cells, liquid biopsy also refers to the investigation of other general body fluids including its constituents characterization and not necessarily related to cancer. In this thesis, three new applications for the usage of label-free markers in the analysis of body fluid cellular constituents will be presented. Digital holographic microscopy and optical tweezers are applied to the characterization of ex-vivo generated and native red blood cells. In a second application, neutrophils precursors are characterized and classified according to its cellular and nuclear morphology during granulocytic differ- entiation. In a third proposed application, morphological markers retrieved by digital holographic microscopy are used to perform fast screening urinalysis, including leukocyturia and bacteriuria. Lastly, although not label-free, fluorescence superresolution microscopy is used to bring insights into why nuclear morphology can be used as a trustful label-free marker and shows the structural arrangement of lamin in the nucleus of neutrophil precursors with unprecedented resolution. Fast screening label-free liquid biopsies integrates the group of emerging approaches that will revolutionize the future of early disease diagnosis and therapeutic choice with disruptive impact on the society. All the investigations described in this Thesis were aimed to contribute to this promising and intriguing new scenario.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Libros sobre el tema "Liquid biopsy"

Chinen, Ludmilla Thomé Domingos, ed. Atlas of Liquid Biopsy. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Russo, Antonio, Antonio Giordano y Christian Rolfo, eds. Liquid Biopsy in Cancer Patients. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-55661-1.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Strumfa, Ilze y Janis Gardovskis, eds. Liquid Biopsy. IntechOpen, 2019. http://dx.doi.org/10.5772/intechopen.73612.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Datar, Ram H., Marija Balic, Siddarth Rawal, Zheng Ao y Anthony Williams. Liquid Biopsy. Elsevier Science & Technology Books, 2019.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Gardovskis, Janis. Liquid Biopsy. IntechOpen, 2019.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Histopathology and Liquid Biopsy [Working Title]. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.87426.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Lianidou, Evi y Richard J. Cote. Circulating Tumor Cells: Advances in Liquid Biopsy Technologies. Springer International Publishing AG, 2023.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Liquid Biopsy in Urogenital Cancers and its Clinical Utility. Elsevier, 2022. http://dx.doi.org/10.1016/c2021-0-00436-3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Aghamir, Seyed Mohammad Kazem. Liquid Biopsy in Urogenital Cancers and Their Clinical Utility. Elsevier Science & Technology, 2022.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Aghamir, Seyed Mohammad Kazem. Liquid Biopsy in Urogenital Cancers and Their Clinical Utility. Elsevier Science & Technology Books, 2022.

Buscar texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Más fuentes

Capítulos de libros sobre el tema "Liquid biopsy"

Snyder, Rebecca A., Arvind Dasari y Y. Nancy You. "Liquid Biopsy". En Colorectal Liver Metastasis, 457–64. Cham: Springer International Publishing, 2022. http://dx.doi.org/10.1007/978-3-031-09323-4_49.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Rao, Jianyu, Weibo Yu, Teresa Kim y Thomas Lee. "Liquid Biopsy". En Clinical Molecular Diagnostics, 377–94. Singapore: Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-16-1037-0_27.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Castiglia, Marta, Lorena Incorvaia, Valerio Gristina, Umberto Malapelle, Viviana Bazan, Christian Rolfo y Antonio Russo. "Liquid Biopsy". En Practical Medical Oncology Textbook, 99–122. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-56051-5_6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ciaccio, Marcello. "Liquid Biopsy". En Clinical and Laboratory Medicine Textbook, 467–73. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24958-7_34.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Roberts, Rene, Bilal A. Siddiqui, Sumit K. Subudhi y Rahul A. Sheth. "Image-Guided Biopsy/Liquid Biopsy". En Image-Guided Interventions in Oncology, 299–318. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-48767-6_18.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Torres, Jacqueline Aparecida y Victor Hugo Fonseca de Jesus. "Circulating Tumor Cells in Gastric Cancer". En Atlas of Liquid Biopsy, 103–26. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_7.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Souza e Silva, Virgilio, Angelo Borsarelli Carvalho de Brito y Daniela Costa. "Circulating Tumor Cells in Colorectal Cancer". En Atlas of Liquid Biopsy, 47–63. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Tariki, Milena Shizue. "Circulating Tumor Cells in Prostate Cancer". En Atlas of Liquid Biopsy, 93–102. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

de Oliveira, Thiago Bueno. "Circulating Tumor Cells in Head and Neck Cancer". En Atlas of Liquid Biopsy, 27–45. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_3.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Braun, Alexcia Camila y José Gabriel Rodríguez Tarazona. "Circulating Tumor Cells in Mesenchymal Tumors". En Atlas of Liquid Biopsy, 127–47. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-69879-9_8.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Actas de conferencias sobre el tema "Liquid biopsy"

Grinyte, Ruta, Thorsten Lux, Mokhtar Chmeissani y Marc Masa. "Photonics Platform For Liquid Biopsy". En Bragg Gratings, Photosensitivity and Poling in Glass Waveguides and Materials. Washington, D.C.: OSA, 2018. http://dx.doi.org/10.1364/bgppm.2018.jtu2a.50.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Kim, Hyunji, Fehmi Civitci, Josiah Wagner, Pavana Anur, Matthew Rames, Xiaolin Nan, Terry Morgan y Thuy Ngo. "Abstract 2286: Liquid biopsy for early cancer detection". En Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-2286.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Mohan, S., V. Foy, HS Leong, M. Carter, L. Priest, C. Faivre-Finn, F. Blackhall, D. Rothwell, C. Dive y G. Brady. "9 Liquid biopsy in small cell lung cancer (SCLC)". En Abstracts of the 25th Biennial Congress of the European Association for Cancer Research, Amsterdam, The Netherlands, 30 June – 3 July 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/esmoopen-2018-eacr25.9.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Sims-Mourtada, Jennifer, Kimberly M. Arnold y Adam Marsh. "Abstract 4545: A liquid biopsy for breast cancer diagnosis". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4545.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Rahimian, Ali, Kyungjin Hong, Clara Neal, Gabriella Iacovetti, Greg Sommer y Ulrich Schaff. "Abstract 3103: TorqTMsystem improves liquid biopsy sample shipping stability". En Proceedings: AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.am2020-3103.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Spaziani, Sara, Giuseppe Quero, Stefano Managò, Gianluigi Zito, Daniela Terracciano, Paolo E. Macchia, Francesco Galeotti, Marco Pisco, Anna C. De Luca y Andrea Cusano. "SERS optrode for human thyroglobulin detection in liquid biopsy". En European Workshop on Optical Fibre Sensors (EWOFS 2023), editado por Marc Wuilpart y Christophe Caucheteur. SPIE, 2023. http://dx.doi.org/10.1117/12.2679428.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Trudel, Suzanne y Trevor Pugh. "Abstract IA11: Clinical applications of liquid biopsy in multiple myeloma". En Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-ia11.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Netto, George J. "Abstract IA26: Liquid biopsy in precision pathology: Plasma and beyond!" En Abstracts: AACR Special Conference on Advances in Liquid Biopsies; January 13-16, 2020; Miami, FL. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1557-3265.liqbiop20-ia26.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Pantel, Klaus. "Abstract PL01-01: Liquid biopsy: Novel technologies and clinical applications". En Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-pl01-01.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Informes sobre el tema "Liquid biopsy"

Liang, Feixin. Progress in Liquid Biopsy: A possible role of neutrophils. Science Repository, agosto de 2018. http://dx.doi.org/10.31487/j.cor.2018.02.004.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Chen, Xuefeng, Haoyu Wang y Yu Wang. The diagnostic value of liquid biopsy for cervical cancer: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, julio de 2022. http://dx.doi.org/10.37766/inplasy2022.7.0122.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Wang, Yu, Hao Yu Wang y Xue Feng Chen. Diagnostic value of different components of liquid biopsy in ovarian cancer: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, julio de 2022. http://dx.doi.org/10.37766/inplasy2022.7.0124.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Wang, Hao Yu, Yu Wang y Xue Feng Chen. Diagnostic performance of various liquid biopsy methods in the detection of gastric cancer: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, julio de 2022. http://dx.doi.org/10.37766/inplasy2022.7.0123.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Chen, Si Yu \. y Hao Yu Wang. Diagnostic performance of various liquid biopsy methods in the detection of upper gastrointestinal cancer: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, noviembre de 2022. http://dx.doi.org/10.37766/inplasy2022.11.0044.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!